Aurobindo Pharma receives US FDA approval for rivastigmine tartrate capsules

By: |
Updated: March 29, 2016 4:06 PM

The product is expected to be launched in Q1 FY16-17

The product is expected to be launched in Q1 FY16-17

Aurobindo Pharma has received final approval from the US Food & Drug Administration (US FDA) to manufacture and market rivastigmine tartrate capsules USP, 1.5 mg, 3 mg, 4.5 mg and 6 mg. The product is expected to be launched in Q1 FY16-17.

The approved ANDA is bioequivalent and therapeutically equivalent to the reference listed drug product (RLD) Exelon capsules, 1.5 mg, 3 mg, 4.5 mg and 6 mg, of Novartis Pharmaceuticals Corporation.

Naproxen sodium tablets is used in the treatment of mild moderate dementia of the Alzheimer’s and Parkinson’s disease. The approved product has an estimated market size of $26.7 million for the twelve months ending January 2016 according to IMS. This is the 67th ANDA (including 14 tentative approvals) to be approved out of Unit VII formulation facility in Hyderabad, India for manufacturing Oral Non-Antibiotic products. Aurobindo now has a total of 246 ANDA approvals (211 Final approvals including 10 from Aurolife Pharma LLC and 35 tentative approvals) from US FDA.

EP News BureauMumbai

Get live Stock Prices from BSE, NSE, US Market and latest NAV, portfolio of Mutual Funds, Check out latest IPO News, Best Performing IPOs, calculate your tax by Income Tax Calculator, know market’s Top Gainers, Top Losers & Best Equity Funds. Like us on Facebook and follow us on Twitter.

Financial Express is now on Telegram. Click here to join our channel and stay updated with the latest Biz news and updates.